Form 4: Cellectar Biosciences COO Jarrod Longcor Acquires 30,000 Shares of Common Stock

Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences, purchased 30,000 shares of common stock at $0.28 per share on January 10, 2025.

Summary

• On January 10, 2025, Jarrod Longcor, the Chief Operating Officer of Cellectar Biosciences, Inc., acquired 30,000 shares of common stock.
• The purchase price was $0.28 per share.
• Following the transaction, Longcor directly owns 83,141 shares of Cellectar Biosciences common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally a good sign, but the size of the purchase is relatively small.

Positives

• The COO's purchase of company stock may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. Monitoring these filings can offer insights into management's perspective on the company's valuation and future performance.

Comparison to Industry Standards

• Insider buying is generally viewed as a positive sign, suggesting that those with the most knowledge of the company believe its stock is undervalued.
• However, the significance of this purchase should be considered in the context of Longcor's overall compensation and holdings.
• A purchase of 30,000 shares is relatively small compared to the total outstanding shares of Cellectar Biosciences.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholder sentiment.

Key Dates